Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Tatenda, Makoni"'
Autor:
Tafadzwa Dzinamarira, Christine Peta, Enos Moyo, Roda Madziva, Rouzeh Eghtessadi, Tatenda Makoni, Godfrey Musuka
Publikováno v:
Health Policy Open, Vol 7, Iss , Pp 100131- (2024)
In this paper, we explore the critical barriers that persons with disabilities face in accessing HIV services in the Eastern and Southern Africa (ESA) region, despite significant advancements in overall accessibility. We highlight the intersectional
Externí odkaz:
https://doaj.org/article/af68fcd9c31b406eb15b93692c3e21ff
Autor:
Tatenda Makoni, Bernard Madzima, Tafadzwa Dzinamarira, Enos Moyo, Amon Mpofu, Innocent Chingombe, Munyaradzi Mapingure, Godfrey Musuka
Publikováno v:
Frontiers in Public Health, Vol 11 (2024)
Externí odkaz:
https://doaj.org/article/d29106716b504e229a33d9c979bcd4ed
Autor:
Munyaradzi P. Mapingure, Jennifer M. Zech, Yael Hirsch‐Moverman, Martin Msukwa, Andrea A. Howard, Tatenda Makoni, Clorata Gwanzura, Tsitsi Apollo, Charles Sandy, Godfrey N. Musuka, Miriam Rabkin
Publikováno v:
Journal of the International AIDS Society, Vol 26, Iss 6, Pp n/a-n/a (2023)
Abstract Introduction Tuberculosis (TB) causes one‐third of HIV‐related deaths worldwide, making TB preventive treatment (TPT) a critical element of HIV programmes. Approximately 16% of people living with HIV (PLHIV) on antiretrovirals in Zimbabw
Externí odkaz:
https://doaj.org/article/1dd25904de204c0fad88f35ed5cecfed
Autor:
Bernard, Madzima, Tatenda, Makoni, Owen, Mugurungi, Godfrey, Mudariki, Amon, Mpofu, Freeman, Dube, Lameck, Munangaidzwa, Isaac, Taramusi
Publikováno v:
African Journal of AIDS Research. 21:194-200
The COVID-19 pandemic was reported from March 2020 in Zimbabwe. COVID-19 containment measures which included repeated lockdowns have disrupted community interactions, reduced working hours, restricted travel and restricted HIV services for people liv
Publikováno v:
Journal of the International AIDS Society. 25
Autor:
Jessica L Ansel, Dan H. Barouch, Kayvon Modjarrad, Katherine E. Yanosick, Lauren Peter, Edward T. Moseley, Rafael De La Barrera, Tatenda Makoni, Michael S. Seaman, Peter Dawson, Rachel Fogel, Joseph P. Nkolola, Kathryn E. Stephenson, Stephen R. Walsh, Andrew J. Hale, Diane G. Kanjilal, Kate Jaegle, Nelson L. Michael, Stephen J. Thomas, Connor Bradshaw, Abishek Chandrashekar, Jason Thompson, Kenneth H. Eckels, Erica N. Borducchi, Anna Tyler, Chen S. Tan
Publikováno v:
Lancet Infect Dis
Summary Background The development of an effective vaccine against Zika virus remains a public health priority. A Zika purified inactivated virus (ZPIV) vaccine candidate has been shown to protect animals against Zika virus challenge and to be well t
Autor:
Catherine Jacob-Dolan, Michael S. Seaman, Carolyn D. Alonso, Macaya Douoguih, Hanneke Schuitemaker, Ruvandhi R. Nathavitharana, Jinyan Liu, Lisa H. Tostanoski, Roger L. Shapiro, Jerald C. Sadoff, Kate Jaegle, Shivani A. Patel, Katherine E. Yanosick, Abishek Chandrashekar, Katherine McMahan, Jessica L Ansel, Chen S. Tan, Dan H. Barouch, Diane G. Kanjilal, Jingyou Yu, Morgana Souza, Douglas A. Lauffenburger, Anna Tyler, Anne Marit de Groot, Caitlin J. Guiney, Frank Struyf, Mathieu Le Gars, Connor Bradshaw, Kathryn E. Stephenson, Joseph P. Nkolola, Carla Truyers, Zhenfeng Li, Rebecca Zash, Boris Julg, Carolin Loos, Caroline Atyeo, Galit Alter, Johan Van Hoof, Dirk Heerwegh, Erica N. Borducchi, Makda S. Gebre, Lauren Peter, Tatenda Makoni, Ahmed Abdul Azim
Publikováno v:
JAMA
Importance Control of the global COVID-19 pandemic will require the development and deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including the ki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c08377b16842fb53684d63f63c34e97
https://europepmc.org/articles/PMC7953339/
https://europepmc.org/articles/PMC7953339/
Autor:
Connor Bradshaw, Stephen R. Walsh, Kathryn E. Stephenson, Abishek Chandrashekar, Darla Quijada, Frank Wegmann, Jeroen Tolboom, Erica N. Borducchi, Rachel Fogel, Jessica L Ansel, Frank Tomaka, Kate Jaegle, C Sabrina Tan, Maria Grazia Pau, Roland Zahn, Jenny Hendriks, Michael S. Seaman, Galit Alter, Steven Nijs, Lauren Peter, Tatenda Makoni, Katherine E. Yanosick, Carla Truyers, Daniel J. Stieh, Dan H. Barouch, Hanneke Schuitemaker, Diane G. Kanjilal, Lisa Howe, Anna Tyler, Joseph P. Nkolola, Esther A. Bondzie, Ludo Lavreys
Publikováno v:
The lancet. HIV. 7(6)
Summary Background Current efficacy studies of a mosaic HIV-1 prophylactic vaccine require four vaccination visits over one year, which is a complex regimen that could prove challenging for vaccine delivery at the community level, both for recipients